

CASI Pharmaceuticals, Inc., a biopharmaceutical company, develops and commercializes therapeutics and pharmaceutical products in China, the United States, and internationally. It offers EVOMELA, an intravenous formulation of melphalan for use as a conditioning treatment prior to stem cell transplantation, and as a palliative treatment for patients with multiple myeloma. The company's product pipel⦠read more
Healthcare
Biotechnology
29 years
USD
Exclusive to Premium users
$1.38
Price+3.76%
$0.05
$21.380m
Small
-
Premium
Premium
-262.4%
EBITDA Margin-320.4%
Net Profit Margin-
Free Cash Flow Margin$31.564m
+10.6%
1y CAGR-8.9%
3y CAGR+4.1%
5y CAGR-$46.890m
-19.4%
1y CAGR-11.2%
3y CAGR-9.5%
5y CAGR-$3.04
-18.7%
1y CAGR-5.1%
3y CAGR-4.8%
5y CAGR-$20.310m
$31.202m
Assets$51.512m
Liabilities$18.734m
Debt60.0%
-0.5x
Debt to EBITDA$0.00
+100.0%
1y CAGR+28.1%
3y CAGR+30.3%
5y CAGR